Our studies suggest that administration of IL-6 or G-CSF signaling inhibitors in the peri-chemotherapy period (at least in patients who might be expected to have a surge of IL-6 or G-CSF levels due to chemotherapy) might decrease tumor recurrence and improve survival outcomes. Here, IL6 is linked to neoplasm.